Pharmacogenomic analyses of targeting the AT-rich malaria parasite genome with AT-specific alkylating drugs.

[1]  Irene K. Moore,et al.  A genomic code for nucleosome positioning , 2006, Nature.

[2]  C. Nickel,et al.  Thioredoxin networks in the malarial parasite Plasmodium falciparum. , 2006, Antioxidants & redox signaling.

[3]  L. Purcell,et al.  The A/T-specific DNA alkylating agent adozelesin inhibits Plasmodium falciparum growth in vitro and protects mice against Plasmodium chabaudi adami infection. , 2006, Molecular and biochemical parasitology.

[4]  A. Fiorini,et al.  Scaffold/matrix attachment regions and intrinsic DNA curvature , 2006, Biochemistry (Moscow).

[5]  L. McRobert,et al.  Evidence on the chromosomal location of centromeric DNA in Plasmodium falciparum from etoposide-mediated topoisomerase-II cleavage. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[6]  P. Osmulski,et al.  Unwound nature of MAR-capable AT-rich DNA domains (AT-islands) targeted by a highly AT-specific drug bizelesin , 2006 .

[7]  R. Pink,et al.  Opportunities and Challenges in Antiparasitic Drug Discovery , 2005, Nature Reviews Drug Discovery.

[8]  S. Hay,et al.  The global distribution of clinical episodes of Plasmodium falciparum malaria , 2005, Nature.

[9]  S. Krishna,et al.  Pharmacokinetic and Pharmacodynamic Issues in the Treatment of Parasitic Infections , 2004, European Journal of Clinical Microbiology and Infectious Diseases.

[10]  J. Woynarowski.  AT islands - their nature and potential for anticancer strategies. , 2004, Current cancer drug targets.

[11]  K. Becker,et al.  The thioredoxin system—From science to clinic , 2004, Medicinal research reviews.

[12]  T. Herman,et al.  Matrix attachment region (MAR) properties and abnormal expansion of AT island minisatellites in FRA16B fragile sites in leukemic CEM cells. , 2003, Nucleic acids research.

[13]  B. Wickstead,et al.  Repetitive Elements in Genomes of Parasitic Protozoa , 2003, Microbiology and Molecular Biology Reviews.

[14]  D. V. Von Hoff,et al.  A phase I study of bizelesin, a highly potent and selective DNA-interactive agent, in patients with advanced solid malignancies. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  I. Hastings.  Malaria control and the evolution of drug resistance: an intriguing link. , 2003, Trends in parasitology.

[16]  Jonathan E. Allen,et al.  Genome sequence of the human malaria parasite Plasmodium falciparum , 2002, Nature.

[17]  Wim G J Hol,et al.  Drugs to Combat Tropical Protozoan Parasites , 2002, Science.

[18]  J. Woynarowski.  Targeting critical regions in genomic DNA with AT-specific anticancer drugs. , 2002, Biochimica et biophysica acta.

[19]  C. Rogier,et al.  In vitro reversal of chloroquine resistance in Plasmodium falciparum with dihydroethanoanthracene derivatives. , 2002, The American journal of tropical medicine and hygiene.

[20]  J. Sloan,et al.  A Phase I study of bizelesin (NSC 615291) in patients with advanced solid tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  T. Richie,et al.  Progress and challenges for malaria vaccines , 2002, Nature.

[22]  L. Hurley,et al.  The genome factor in region-specific DNA damage: the DNA-reactive drug U-78779 prefers mixed A/T-G/C sequences at the nucleotide level but is region-specific for long pure AT islands at the genomic level. , 2002, Biochemistry.

[23]  R. Snow,et al.  Clinical status and implications of antimalarial drug resistance. , 2002, Microbes and infection.

[24]  C. Benham,et al.  AT-rich Islands in Genomic DNA as a Novel Target for AT-specific DNA-reactive Antitumor Drugs* 210 , 2001, The Journal of Biological Chemistry.

[25]  P. Rangarajan,et al.  Emerging targets for antimalarial drugs , 2001, Expert opinion on therapeutic targets.

[26]  R. Schirmer,et al.  Thioredoxin reductase as a pathophysiological factor and drug target. , 2000, European journal of biochemistry.

[27]  C. Napier,et al.  Region-specific DNA damage by AT-specific DNA-reactive drugs is predicted by drug binding specificity. , 2000, Biochemistry.

[28]  J. Woynarowski,et al.  Tallimustine lesions in cellular DNA are AT sequence-specific but not region-specific. , 1999, Biochemistry.

[29]  C. Napier,et al.  Induction of AT-specific DNA-interstrand crosslinks by bizelesin in genomic and simian virus 40 DNA. , 1999, Biochimica et biophysica acta.

[30]  C. Napier,et al.  Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA. , 1998, Molecular pharmacology.

[31]  G. Hortobagyi,et al.  Phase II study of adozelesin in untreated metastatic breast cancer , 1998, Anti-cancer drugs.

[32]  M. Palumbo.  Advances in DNA Sequence Specific Agents , 1998 .

[33]  A. Crisanti,et al.  Antimalarial activity of synthetic analogues of distamycin. , 1997, Pharmacology & therapeutics.

[34]  I. Sherman,et al.  The sticky secrets of sequestration. , 1995, Parasitology today.

[35]  V. Bhasin,et al.  Cure with cisplatin (II) or murine malaria infection and in vitro inhibition of a chloroquine-resistant Plasmodium falciparum isolate. , 1994, Japanese journal of medical science & biology.

[36]  R. Schilsky,et al.  Phase I study of adozelesin administered by 24-hour continuous intravenous infusion. , 1994, Journal of the National Cancer Institute.

[37]  M. Mitchell,et al.  In vivo mutagenesis induced by CC-1065 and adozelesin DNA alkylation in a transgenic mouse model. , 1993, Cancer research.

[38]  J. Inselburg,et al.  In vitro sensitivity of Plasmodium falciparum to drugs that bind DNA or inhibit its synthesis. , 1993, The Journal of parasitology.

[39]  H. Ginsburg,et al.  The susceptibility of the malarial parasite Plasmodium falciparum to quinoline-containing drugs is correlated to the lipid composition of the infected erythrocyte membranes. , 1993, Biochemical pharmacology.

[40]  L. Hurley,et al.  Analysis of the monoalkylation and cross-linking sequence specificity of bizelesin, a bifunctional alkylation agent related to (+)-CC-1065 , 1993 .

[41]  N. Gibson,et al.  Nucleotide preferences for DNA interstrand cross-linking induced by the cyclopropylpyrroloindole analogue U-77,779. , 1993, Biochemistry.

[42]  H. Ginsburg,et al.  Selective toxicity to malaria parasites by non-intercalating DNA-binding ligands. , 1993, Molecular and biochemical parasitology.

[43]  F. T. Ter Kuile,et al.  Plasmodium falciparum: in vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria. , 1993, Experimental parasitology.

[44]  K. L. Weiland,et al.  In vitro and in vivo DNA bonding by the CC-1065 analogue U-73975. , 1991, Biochemistry.

[45]  J. Jensen,et al.  Stage specific actions of antimalarial drugs on Plasmodium falciparum in culture. , 1989, The American journal of tropical medicine and hygiene.

[46]  J. Haynes,et al.  Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique , 1979, Antimicrobial Agents and Chemotherapy.

[47]  C. Lambros,et al.  Synchronization of Plasmodium falciparum erythrocytic stages in culture. , 1979, The Journal of parasitology.

[48]  Zhandong Liu,et al.  In silico and wet-bench identification of nuclear matrix attachment regions. , 2005, Methods in molecular medicine.

[49]  D. Walker,et al.  Preclinical pharmacology of bizelesin, a potent bifunctional analog of the DNA-binding antibiotic CC-1065 , 2004, Cancer Chemotherapy and Pharmacology.

[50]  J. Woynarowski.  Preferential damage to defined regions of genomic DNA by AT-specific anticancer drugs , 2002 .

[51]  G. Benson,et al.  Tandem repeats finder: a program to analyze DNA sequences. , 1999, Nucleic acids research.

[52]  H. Naegeli,et al.  A repair competition assay to assess recognition by human nucleotide excision repair. , 1996, Nucleic acids research.

[53]  H. Ginsburg,et al.  Studies on the antimalarial mode of action of quinoline-containing drugs: time-dependence and irreversibility of drug action, and interactions with compounds that alter the function of the parasite's food vacuole. , 1991, Life sciences.